FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135402263> ?p ?o ?g. }

• W2135402263 endingPage "450" @default.
• W2135402263 startingPage "437" @default.
• W2135402263 abstract "WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Multiple treatment alternatives exist for localised prostate cancer, with few high-quality studies directly comparing their comparative effectiveness and costs. The present study is the most comprehensive cost-effectiveness analysis to date for localised prostate cancer, conducted with a lifetime horizon and accounting for survival, health-related quality-of-life, and cost impact of secondary treatments and other downstream events, as well as primary treatment choices. The analysis found minor differences, generally slightly favouring surgical methods, in quality-adjusted life years across treatment options. However, radiation therapy (RT) was consistently more expensive than surgery, and some alternatives, e.g. intensity-modulated RT for low-risk disease, were dominated - that is, both more expensive and less effective than competing alternatives.To characterise the costs and outcomes associated with radical prostatectomy (open, laparoscopic, or robot-assisted) and radiation therapy (RT: dose-escalated three-dimensional conformal RT, intensity-modulated RT, brachytherapy, or combination), using a comprehensive, lifetime decision analytical model.A Markov model was constructed to follow hypothetical men with low-, intermediate-, and high-risk prostate cancer over their lifetimes after primary treatment; probabilities of outcomes were based on an exhaustive literature search yielding 232 unique publications. In each Markov cycle, patients could have remission, recurrence, salvage treatment, metastasis, death from prostate cancer, and death from other causes. Utilities for each health state were determined, and disutilities were applied for complications and toxicities of treatment. Costs were determined from the USA payer perspective, with incorporation of patient costs in a sensitivity analysis.Differences across treatments in quality-adjusted life years across methods were modest, ranging from 10.3 to 11.3 for low-risk patients, 9.6-10.5 for intermediate-risk patients and 7.8-9.3 for high-risk patients. There were no statistically significant differences among surgical methods, which tended to be more effective than RT methods, with the exception of combined external beam + brachytherapy for high-risk disease. RT methods were consistently more expensive than surgical methods; costs ranged from $19 901 (robot-assisted prostatectomy for low-risk disease) to $50 276 (combined RT for high-risk disease). These findings were robust to an extensive set of sensitivity analyses.Our analysis found small differences in outcomes and substantial differences in payer and patient costs across treatment alternatives. These findings may inform future policy discussions about strategies to improve efficiency of treatment selection for localised prostate cancer." @default.
• W2135402263 created "2016-06-24" @default.
• W2135402263 creator A5006318553 @default.
• W2135402263 creator A5007337539 @default.
• W2135402263 creator A5031546223 @default.
• W2135402263 creator A5068285584 @default.
• W2135402263 creator A5073175568 @default.
• W2135402263 creator A5075209273 @default.
• W2135402263 creator A5081519171 @default.
• W2135402263 date "2012-12-28" @default.
• W2135402263 modified "2023-09-27" @default.
• W2135402263 title "Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis" @default.
• W2135402263 cites W1980710500 @default.
• W2135402263 cites W1983145936 @default.
• W2135402263 cites W2028639699 @default.
• W2135402263 cites W2036291769 @default.
• W2135402263 cites W2039536878 @default.
• W2135402263 cites W2041238968 @default.
• W2135402263 cites W2043945205 @default.
• W2135402263 cites W2043978545 @default.
• W2135402263 cites W2051717098 @default.
• W2135402263 cites W2053198390 @default.
• W2135402263 cites W2054899405 @default.
• W2135402263 cites W2070912263 @default.
• W2135402263 cites W2071879495 @default.
• W2135402263 cites W2076071526 @default.
• W2135402263 cites W2081994609 @default.
• W2135402263 cites W2083074823 @default.
• W2135402263 cites W2087810839 @default.
• W2135402263 cites W2089983916 @default.
• W2135402263 cites W2099975465 @default.
• W2135402263 cites W2105959001 @default.
• W2135402263 cites W2107251918 @default.
• W2135402263 cites W2107671263 @default.
• W2135402263 cites W2108081829 @default.
• W2135402263 cites W2109487148 @default.
• W2135402263 cites W2110569728 @default.
• W2135402263 cites W2115047638 @default.
• W2135402263 cites W2120993630 @default.
• W2135402263 cites W2133379066 @default.
• W2135402263 cites W2134773558 @default.
• W2135402263 cites W2137491531 @default.
• W2135402263 cites W2140756266 @default.
• W2135402263 cites W2141198296 @default.
• W2135402263 cites W2142658264 @default.
• W2135402263 cites W2147876556 @default.
• W2135402263 cites W2150505942 @default.
• W2135402263 cites W2156549595 @default.
• W2135402263 cites W2157996158 @default.
• W2135402263 cites W2158631186 @default.
• W2135402263 cites W2159790321 @default.
• W2135402263 cites W2160217483 @default.
• W2135402263 cites W2321200854 @default.
• W2135402263 cites W3023689102 @default.
• W2135402263 doi "https://doi.org/10.1111/j.1464-410x.2012.11597.x" @default.
• W2135402263 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3587031" @default.
• W2135402263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23279038" @default.
• W2135402263 hasPublicationYear "2012" @default.
• W2135402263 type Work @default.
• W2135402263 sameAs 2135402263 @default.
• W2135402263 citedByCount "105" @default.
• W2135402263 countsByYear W21354022632013 @default.
• W2135402263 countsByYear W21354022632014 @default.
• W2135402263 countsByYear W21354022632015 @default.
• W2135402263 countsByYear W21354022632016 @default.
• W2135402263 countsByYear W21354022632017 @default.
• W2135402263 countsByYear W21354022632018 @default.
• W2135402263 countsByYear W21354022632019 @default.
• W2135402263 countsByYear W21354022632020 @default.
• W2135402263 countsByYear W21354022632021 @default.
• W2135402263 countsByYear W21354022632022 @default.
• W2135402263 countsByYear W21354022632023 @default.
• W2135402263 crossrefType "journal-article" @default.
• W2135402263 hasAuthorship W2135402263A5006318553 @default.
• W2135402263 hasAuthorship W2135402263A5007337539 @default.
• W2135402263 hasAuthorship W2135402263A5031546223 @default.
• W2135402263 hasAuthorship W2135402263A5068285584 @default.
• W2135402263 hasAuthorship W2135402263A5073175568 @default.
• W2135402263 hasAuthorship W2135402263A5075209273 @default.
• W2135402263 hasAuthorship W2135402263A5081519171 @default.
• W2135402263 hasBestOaLocation W21354022632 @default.
• W2135402263 hasConcept C112930515 @default.
• W2135402263 hasConcept C121608353 @default.
• W2135402263 hasConcept C126322002 @default.
• W2135402263 hasConcept C141071460 @default.
• W2135402263 hasConcept C143998085 @default.
• W2135402263 hasConcept C159110408 @default.
• W2135402263 hasConcept C177713679 @default.
• W2135402263 hasConcept C2776235491 @default.
• W2135402263 hasConcept C2777416452 @default.
• W2135402263 hasConcept C2779466945 @default.
• W2135402263 hasConcept C2779951463 @default.
• W2135402263 hasConcept C2780192828 @default.
• W2135402263 hasConcept C3019080777 @default.
• W2135402263 hasConcept C509974204 @default.
• W2135402263 hasConcept C64332521 @default.
• W2135402263 hasConcept C71924100 @default.
• W2135402263 hasConceptScore W2135402263C112930515 @default.

• next